Alle Fotos(2)
Wichtige Dokumente
RAB0242
Human IgG1 ELISA Kit
for serum, plasma, conditioned medium, urine
Synonym(e):
IgG1, Immunoglobulin G1
Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(2)
About This Item
UNSPSC-Code:
41116158
NACRES:
NA.32
Empfohlene Produkte
Speziesreaktivität
human
Verpackung
kit of 96 wells (12 strips x 8 wells)
Methode(n)
ELISA: suitable
capture ELISA: suitable
Aufnahme
sample type plasma
sample type serum
sample type conditioned medium
sample type urine
assay range
inter-assay cv: <12%
intra-assay cv: <10%
sensitivity: 50 pg/mL
standard curve range: 0.05-40 ng/mL
Nachweisverfahren
colorimetric
Versandbedingung
wet ice
Lagertemp.
−20°C
Angaben zum Gen
human ... IGHG1(3500)
Allgemeine Beschreibung
The Human IgG1 ELISA (Enzyme-Linked Immunosorbent Assay) kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of human IgG1 in serum and plasma.
Immunogen
Recombinant Human IGG1
Anwendung
For research use only. Not for use in diagnostic procedures.
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)
Biochem./physiol. Wirkung
Immunoglobulin heavy constant gamma 1 (IGHG1), or IgG1, expressed in pancreatic cancer cells might be implicated in tumor cell proliferation and immune evasion mechanisms. siRNA targeted silencing of IGHG1 retards cell growth and induces apoptosis in human prostate cancer cell.
Sonstige Hinweise
A sample Certificate of Analysis is available for this product.
Please type the word sample in the text box provided for lot number.
Please type the word sample in the text box provided for lot number.
Signalwort
Warning
H-Sätze
P-Sätze
Gefahreneinstufungen
Met. Corr. 1
Lagerklassenschlüssel
8A - Combustible corrosive hazardous materials
Hier finden Sie alle aktuellen Versionen:
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
Kunden haben sich ebenfalls angesehen
Roxanne Collin et al.
Journal of immunology (Baltimore, Md. : 1950), 193(7), 3503-3512 (2014-08-29)
Autoimmune diseases result from a break in immune tolerance. Various mechanisms of peripheral tolerance can protect against autoimmunity, including immunoregulatory CD4(-)CD8(-) double-negative (DN) T cells. Indeed, we have previously shown that diabetes-prone mouse strains exhibit a low proportion of DN
Xiaoyan Li et al.
Pancreas, 40(5), 753-761 (2011-06-10)
To investigate the expression of Igγ-1 chain C region (IGHG1) in human pancreatic carcinomas and determine the biological function of IGHG1 expression in immune evasion mechanisms. Comparative proteomic analysis was used to detect the differential expression of IGHG1 in human
Bin Pan et al.
Molecular biology reports, 40(1), 27-33 (2012-11-03)
To investigate the immunoglobulin G (IgG) expression in prostate cancer cell lines and explore the effects of IGHG1 gene knockdown on PC3 cell growth and apoptosis. Flow cytometry, qPCR and western blot were used to demonstrate IgG expression in prostate
Arjan van der Flier et al.
PloS one, 10(4), e0124930-e0124930 (2015-04-24)
We recently developed a longer lasting recombinant factor VIII-Fc fusion protein, rFVIIIFc, to extend the half-life of replacement FVIII for the treatment of people with hemophilia A. In order to elucidate the biological mechanism for the elongated half-life of rFVIIIFc
Chanjuan Shen et al.
Vaccine, 32(41), 5337-5342 (2014-08-06)
A better understanding of immune responses in human infants could lead to more effective immunization and vaccination strategies in early life. Since antibodies are key components of protective vaccine responses, we examined developmental changes in serum levels of immunoglobulins (IgG
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung.